peterschreiber.media RBC Capital Markets has lowered its rating on Sage Therapeutics ( NASDAQ: SAGE ) to underperform ahead of readouts for the company’s drug dalzanemdor. As part of its Q3 sector earnings preview, the investment bank said that while it continues to see a $350M to $400M.
